Brokerages forecast that ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) will post earnings of $0.79 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for ANI Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.75 and the highest estimate coming in at $0.82. ANI Pharmaceuticals posted earnings of $0.99 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 20.2%. The firm is scheduled to report its next earnings report on Thursday, August 3rd.

According to Zacks, analysts expect that ANI Pharmaceuticals will report full year earnings of $3.52 per share for the current year, with EPS estimates ranging from $3.43 to $3.60. For the next year, analysts forecast that the firm will report earnings of $4.32 per share, with EPS estimates ranging from $4.07 to $4.56. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for ANI Pharmaceuticals.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, May 4th. The specialty pharmaceutical company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.70 by $0.04. ANI Pharmaceuticals had a net margin of 2.58% and a return on equity of 23.76%. The company had revenue of $36.60 million for the quarter, compared to analysts’ expectations of $39.63 million. During the same quarter in the previous year, the business posted $0.76 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 77.7% on a year-over-year basis.

Several equities analysts recently commented on the stock. Roth Capital set a $56.00 target price on shares of ANI Pharmaceuticals and gave the company a “hold” rating in a report on Saturday, May 6th. Guggenheim reaffirmed a “buy” rating and set a $80.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, July 4th. ValuEngine lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th. Finally, TheStreet lowered shares of ANI Pharmaceuticals from a “b-” rating to a “c” rating in a report on Monday, April 3rd. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. ANI Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $68.50.

WARNING: “Zacks: Analysts Expect ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Will Announce Earnings of $0.79 Per Share” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/20/zacks-analysts-expect-ani-pharmaceuticals-inc-nasdaqanip-will-announce-earnings-of-0-79-per-share.html.

A number of large investors have recently made changes to their positions in ANIP. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of ANI Pharmaceuticals during the first quarter valued at $238,000. Ranger Investment Management L.P. purchased a new stake in shares of ANI Pharmaceuticals during the first quarter valued at $769,000. Tudor Investment Corp ET AL boosted its stake in shares of ANI Pharmaceuticals by 80.4% in the first quarter. Tudor Investment Corp ET AL now owns 8,300 shares of the specialty pharmaceutical company’s stock valued at $411,000 after buying an additional 3,700 shares during the last quarter. Paloma Partners Management Co boosted its stake in shares of ANI Pharmaceuticals by 53.3% in the first quarter. Paloma Partners Management Co now owns 29,783 shares of the specialty pharmaceutical company’s stock valued at $1,475,000 after buying an additional 10,351 shares during the last quarter. Finally, Nomura Holdings Inc. boosted its stake in shares of ANI Pharmaceuticals by 0.6% in the first quarter. Nomura Holdings Inc. now owns 208,901 shares of the specialty pharmaceutical company’s stock valued at $10,352,000 after buying an additional 1,164 shares during the last quarter. 55.51% of the stock is owned by institutional investors and hedge funds.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded up 0.29% during midday trading on Thursday, reaching $48.48. 4,151 shares of the company traded hands. ANI Pharmaceuticals has a 1-year low of $42.56 and a 1-year high of $70.92. The firm has a market capitalization of $564.16 million, a PE ratio of 151.50 and a beta of 3.06. The stock has a 50 day moving average price of $46.27 and a 200 day moving average price of $51.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.